Conference
Real-world utilization and safety of ipilimumab plus nivolumab (I+N) in metastatic renal cell carcinoma (mRCC) patients: Results from the Canadian Kidney Cancer Information System (CKCis).
Abstract
633
Background: I+N is now standard of care for first line treatment of intermediate/poor risk mRCC patients (pts). Real world data is vital to understand drug usage, toxicity and outcomes in non-trial pts. This project describes the amount and tolerability of treatment delivered including discontinuation rates, reasons for discontinuation and outcomes from the CKCis database. Methods: Pts in CKCis, a prospective Canadian …
Authors
Thana M; Basappa NS; Ghosh S; Kollmannsberger CK; Heng DYC; Graham J; Soulieres D; Hansen AR; Lalani A-KA; Castonguay V
Volume
38
Pagination
pp. 633-633
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
February 20, 2020
DOI
10.1200/jco.2020.38.6_suppl.633
Conference proceedings
Journal of Clinical Oncology
Issue
6_suppl
ISSN
0732-183X